The Latest Breaking News from Eli Lilly and Company

Donanemab has been found to slow down the disease in a clinical trial.

Experts say ‘we’re entering a new era where Alzheimer’s disease could become treatable’

With the Fed signaling to continue raising interest rates throughout this year, the probability of the economy tipping into a recession is increasing. Amid the macroeconomic unrest, fundamentally sound large-cap stocks UnitedHealth Group (UNH), Walmart (WMT), and Eli Lilly (LLY) might be safe investments this year. Read on….

The US economy added 261,000 jobs in October, while the unemployment rate increased to 3.7% during the month. Investors, meanwhile, focused on some notable insider trades.

Although the stock market has been under pressure this year due to macroeconomic headwinds, the pharmaceutical industry continues to garner investor attention as it enjoys inelastic demand for its products regardless of economic conditions. Thus, fundamentally-sound pharma stocks Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) could be worth your attention…

Despite the Fed’s continued hawkish stance, the September inflation report came in hotter than expected, raising the possibility of another aggressive interest rate hike in November. However, it could be smart to keep investing in quality stocks to benefit from their rebound. We think Microsoft (MSFT), Eli Lilly (LLY), and…

With the economy reporting two consecutive quarters of GDP decline, many analysts believe that the economy has already entered a recession. During periods of market uncertainty, investors should look for stocks that could win in the long run based on their strong fundamentals and solid growth prospects. We think Pfizer…

Rising inflation, the Fed’s hawkish stance to tame it, and an economic contraction for two consecutive quarters have stoked fears of a recession in the U.S. economy. Amid the likely economic downturn, investors could consider investing in stocks that provide a steady income in the form of dividends. Therefore, we…

The biotech industry flourished during the height of the COVID-19 pandemic and reported record revenues and earnings last year. Despite the market slowdown, the sector is poised for another bull run, given the continued global fight against COVID-19 and the increasing demand with an aging population. Popular biotech stocks Pfizer…